AxoGen (NASDAQ: AXGN) is one of 46 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare AxoGen to similar businesses based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.
Valuation and Earnings
This table compares AxoGen and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AxoGen||$60.43 million||-$10.44 million||-128.06|
|AxoGen Competitors||$1.10 billion||$121.87 million||-38.49|
This is a breakdown of current recommendations for AxoGen and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AxoGen currently has a consensus price target of $33.14, suggesting a potential downside of 16.52%. As a group, “Electromedical equipment” companies have a potential upside of 18.66%. Given AxoGen’s peers higher possible upside, analysts clearly believe AxoGen has less favorable growth aspects than its peers.
Insider and Institutional Ownership
67.8% of AxoGen shares are owned by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 7.9% of AxoGen shares are owned by company insiders. Comparatively, 20.2% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares AxoGen and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
AxoGen has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, AxoGen’s peers have a beta of 1.57, indicating that their average share price is 57% more volatile than the S&P 500.
AxoGen peers beat AxoGen on 9 of the 13 factors compared.
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.